Envafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors-Reference-Cited by-同舟云学术

Envafolimab – first PD-1/PD-L1 antibody to be administered by subcutaneous injection for microsatellite instability-high or deficient mismatch repair advanced solid tumors

Published:2022-09-20 Issue:10 Volume:22 Page:1227-1232
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Chen Mifen¹,Jiang Mengyun²,Wang Xinhui²,Shen Lin¹,Li Jian¹

Affiliation:

1. Department of Gastrointestinal Oncology, Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, China

2. State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Pharmaceutical Co., Ltd, Nanjing, Jiangsu, China

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2022.2125799

Reference37 articles.

1. Regulation and Function of the PD-L1 Checkpoint

2. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

3. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors

4. PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?

5. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Trend of the Treatment of Advanced Hepatocellular Carcinoma: Combination of Immunotherapy and Targeted Therapy;Current Treatment Options in Oncology;2024-09-11

2. Model-informed drug development of envafolimab, a subcutaneously injectable PD-L1 antibody, in patients with advanced solid tumors;The Oncologist;2024-07-09

3. Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature review;Immunotherapy;2024-05-17

4. Chidamide plus envafolimab as subsequent treatment in advanced non‐small cell lung cancer patients resistant to anti‐PD‐1 therapy: A multicohort, open‐label, phase II trial with biomarker analysis;Cancer Medicine;2024-04

5. Immune‑mediated hepatitis and hepatitis B virus reactivation induced by immunotherapy in hepatocellular carcinoma: A case report and literature review;2024-03-28